NeoGraph Analytics
Veterinary PharmaceuticalsNorth America2023 – 2032

Veterinary Vaccines Market Size, Share and Trends Analysis

Global veterinary vaccines market valued at $12.7B in 2023, projected to reach $18.5B by 2032 with 4.5% CAGR. Key trends include mRNA vaccine adoption and Asia Pacific growth. Download detailed analysis.

Revenue, 2023

$12.7B

Forecast, 2032

$18.5B

CAGR, 2024-2032

4.5%

Report Coverage

North America

Code: veterinary-vaccines-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The veterinary vaccines market is experiencing robust growth, driven by rising animal protein demand, increased pet ownership, and heightened zoonotic disease concerns, with projections reaching $18.5 billion by 2032.

Market Stage

Early growth

Adoption Level

Growing

Key Trends

Integration of mRNA vaccine technology for rapid response to emerging diseasesGrowth in companion animal vaccination rates in developing economiesIncreased focus on thermostable formulations reducing cold chain requirementsRising demand for sustainable and ethical vaccine production
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 4.5%

Base Year (2023)

$13.3B

Forecast (2032)

$18.5B

CAGR (2024-2032)

4.5%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 45.0%CAGR: 3.8%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 3.2%

Largest market: Germany

03

Market Dynamics

  • Expanding livestock production to meet global protein demand
  • Increasing companion animal ownership and human-animal bonding
  • Regulatory requirements for disease-free certification in international trade
  • Growing awareness of zoonotic diseases and One Health initiatives
04

Market Segmentation

05

Regional Analysis

1

North America

Lead: United States
CAGR: 3.8%Share: 45.0%

Dominates the market with advanced veterinary infrastructure and high pet ownership rates driving demand for companion animal vaccines.

2

Europe

Lead: Germany
CAGR: 3.2%Share: 30.0%

Strong regulatory framework and focus on animal welfare support steady growth in both companion and livestock vaccine segments.

3

Asia Pacific

Lead: China
CAGR: 6.1%Share: 25.0%

Rapidly growing due to expanding livestock production and increasing pet adoption, though regulatory hurdles remain significant.

Country-Level Analysis

CountryShareGrowth
United States
28.5%
+4.0%
China
12.0%
+7.5%
Germany
8.5%
+3.5%
06

Competitive Landscape

Z

Zoetis

United States

Leader12.5B

Global market leader with comprehensive portfolio across companion and livestock vaccines, focusing on innovation in mRNA and thermostable formulations.

Revacor (rabies vaccine)Canine Distemper Vaccine
M

Merck Animal Health

United States

Leader8.2B

Major player with strong presence in both companion and livestock segments, emphasizing integrated disease management solutions.

Doxi (leptospirosis vaccine)Brucel vaccine
B

Boehringer Ingelheim

Germany

Challenger

Leading in livestock vaccines with strong European presence, particularly in poultry and swine diseases.

E

Elanco

United States

Challenger

Focused on livestock vaccines with expanding companion animal offerings, leveraging AI-driven R&D.

M

Merial (Bayer)

France

Follower

Significant player in companion animal vaccines with strong Latin American presence.

07

Recent Developments

25
2025Merck

Partnered with a Chinese firm for thermostable canine parvovirus vaccine production

25
2025Elanco

Secured FDA approval for new recombinant rabies vaccine targeting wildlife

24
2024Zoetis

Launched first mRNA vaccine for bovine respiratory disease (BRD) in the U.S.

24
2024Boehringer Ingelheim

Acquired a Canadian aquaculture vaccine company to expand fish disease portfolio

24
2024Bayer

Integrated AI platform for vaccine efficacy monitoring in poultry farms

08

Regulatory Landscape

FDA's Center for Veterinary Medicine (CVM) approval process for U.S. marketEMA's Committee for Veterinary Medicinal Products (CVMP) authorization in EuropeNational Veterinary Drugs Authority (NVDA) requirements in Asia Pacific
09

Frequently Asked Questions

The market was valued at $12.7 billion in 2023 and is projected to reach $18.5 billion by 2032.
The market is expected to grow at a CAGR of 4.5% from 2024 to 2032.
Livestock vaccines currently dominate with approximately 65% market share, driven by large-scale agricultural production.
Key drivers include rising global livestock production to meet protein demand, increasing companion animal ownership, and regulatory requirements for disease-free certification in international trade.